Each piece of data contributes to a larger epidemiological picture that will not only help us fight new coronaviruses that emerge in the future, but other infectious diseases as well.
Amid the spread of COVID-19, testing for SARS-COV-2, the virus that causes it, is at the forefront of the battle. Patients rely on test results to confirm if they’ve acquired the coronavirus, and public health entities around globe rely on the data to learn how and where the virus is spreading.
Patients at the greatest risk for secondary infections, particularly infections that are resistant to first-line antibiotics, include people who are already vulnerable due to other conditions and diseases—like COVID-19. Because of that, antimicrobial resistance poses a significant additional threat, especially as healthcare systems become overburdened.
It is especially important to focus on prevention methods amid the COVID-19 pandemic—in previous reports of SARS and MERS-CoV infections, AKI developed in 5% to 15% of cases and carried an extremely high (60%-90%) mortality rate.